Urogen Pharma Ltd
NASDAQ:URGN
Income Statement
Earnings Waterfall
Urogen Pharma Ltd
Revenue
|
82.7m
USD
|
Cost of Revenue
|
-9.4m
USD
|
Gross Profit
|
73.4m
USD
|
Operating Expenses
|
-138.9m
USD
|
Operating Income
|
-65.5m
USD
|
Other Expenses
|
-36.7m
USD
|
Net Income
|
-102.2m
USD
|
Income Statement
Urogen Pharma Ltd
Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
18
N/A
|
18
+0%
|
18
N/A
|
25
+45%
|
8
-68%
|
9
+6%
|
9
+4%
|
1
-84%
|
1
-22%
|
1
-43%
|
0
-53%
|
0
-93%
|
0
N/A
|
0
N/A
|
0
+1 750%
|
4
+935%
|
12
+208%
|
19
+63%
|
32
+66%
|
40
+25%
|
48
+21%
|
54
+13%
|
58
+7%
|
62
+8%
|
64
+3%
|
68
+6%
|
73
+7%
|
77
+7%
|
83
+7%
|
|
Gross Profit | |||||||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
(6)
|
(7)
|
(8)
|
(8)
|
(9)
|
(9)
|
(9)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
18
N/A
|
18
N/A
|
18
N/A
|
25
+43%
|
8
-70%
|
8
+1%
|
8
+1%
|
(1)
N/A
|
(1)
-8%
|
(1)
-6%
|
(1)
-4%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+1 500%
|
3
+984%
|
11
+211%
|
17
+61%
|
29
+65%
|
36
+24%
|
43
+20%
|
48
+13%
|
52
+7%
|
55
+8%
|
57
+2%
|
60
+5%
|
64
+7%
|
68
+7%
|
73
+8%
|
|
Operating Income | |||||||||||||||||||||||||||||||||
Operating Expenses |
(11)
|
(14)
|
(20)
|
(17)
|
(17)
|
(19)
|
(21)
|
(28)
|
(38)
|
(50)
|
(63)
|
(77)
|
(85)
|
(91)
|
(94)
|
(110)
|
(126)
|
(134)
|
(143)
|
(138)
|
(132)
|
(134)
|
(135)
|
(135)
|
(136)
|
(136)
|
(134)
|
(136)
|
(139)
|
(139)
|
(139)
|
(139)
|
|
Selling, General & Administrative |
(2)
|
(3)
|
(6)
|
(6)
|
(6)
|
(8)
|
(7)
|
(9)
|
(14)
|
(22)
|
(30)
|
(40)
|
(46)
|
(50)
|
(53)
|
(60)
|
(69)
|
(80)
|
(88)
|
(90)
|
(90)
|
(89)
|
(88)
|
(88)
|
(87)
|
(85)
|
(83)
|
(83)
|
(86)
|
(88)
|
(90)
|
(93)
|
|
Research & Development |
(9)
|
(11)
|
(14)
|
(10)
|
(10)
|
(12)
|
(14)
|
(19)
|
(24)
|
(28)
|
(32)
|
(37)
|
(39)
|
(41)
|
(41)
|
(49)
|
(56)
|
(54)
|
(55)
|
(47)
|
(41)
|
(45)
|
(47)
|
(48)
|
(50)
|
(50)
|
(52)
|
(53)
|
(53)
|
(52)
|
(49)
|
(46)
|
|
Operating Income |
(11)
N/A
|
(14)
-32%
|
(20)
-44%
|
1
N/A
|
1
+6%
|
(2)
N/A
|
4
N/A
|
(20)
N/A
|
(30)
-51%
|
(43)
-42%
|
(63)
-49%
|
(77)
-22%
|
(86)
-11%
|
(91)
-6%
|
(94)
-3%
|
(109)
-17%
|
(126)
-15%
|
(134)
-6%
|
(139)
-4%
|
(127)
+9%
|
(114)
+10%
|
(105)
+8%
|
(100)
+5%
|
(92)
+7%
|
(88)
+4%
|
(84)
+5%
|
(79)
+6%
|
(79)
0%
|
(79)
0%
|
(76)
+4%
|
(71)
+6%
|
(66)
+8%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||||||||
Interest Income Expense |
(0)
|
0
|
(2)
|
(3)
|
(3)
|
(3)
|
(1)
|
(0)
|
0
|
1
|
1
|
2
|
3
|
3
|
4
|
5
|
4
|
4
|
3
|
2
|
1
|
1
|
1
|
0
|
(0)
|
(2)
|
(5)
|
(8)
|
(10)
|
(11)
|
(12)
|
(12)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(3)
|
(10)
|
(17)
|
(23)
|
(26)
|
(24)
|
(21)
|
(21)
|
(21)
|
(21)
|
(21)
|
|
Pre-Tax Income |
(11)
N/A
|
(14)
-31%
|
(22)
-57%
|
(2)
+91%
|
(2)
+7%
|
(5)
-159%
|
3
N/A
|
(20)
N/A
|
(30)
-50%
|
(42)
-39%
|
(62)
-48%
|
(76)
-22%
|
(84)
-11%
|
(88)
-5%
|
(90)
-2%
|
(105)
-17%
|
(121)
-16%
|
(130)
-7%
|
(137)
-5%
|
(125)
+9%
|
(113)
+9%
|
(108)
+5%
|
(109)
-1%
|
(109)
0%
|
(112)
-2%
|
(112)
-1%
|
(107)
+5%
|
(108)
-1%
|
(110)
-2%
|
(108)
+2%
|
(104)
+3%
|
(98)
+6%
|
|
Net Income | |||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
(4)
|
(4)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(4)
|
|
Income from Continuing Operations |
(11)
|
(14)
|
(22)
|
(2)
|
(2)
|
(5)
|
3
|
(20)
|
(30)
|
(42)
|
(62)
|
(76)
|
(84)
|
(88)
|
(90)
|
(105)
|
(121)
|
(130)
|
(137)
|
(128)
|
(117)
|
(112)
|
(113)
|
(111)
|
(113)
|
(114)
|
(109)
|
(110)
|
(112)
|
(109)
|
(105)
|
(102)
|
|
Net Income (Common) |
(12)
N/A
|
(16)
-34%
|
(24)
-55%
|
(4)
+82%
|
(4)
+4%
|
(7)
-59%
|
2
N/A
|
(21)
N/A
|
(30)
-45%
|
(42)
-38%
|
(62)
-48%
|
(76)
-22%
|
(84)
-11%
|
(88)
-5%
|
(90)
-2%
|
(105)
-17%
|
(121)
-16%
|
(130)
-7%
|
(137)
-5%
|
(128)
+6%
|
(117)
+9%
|
(112)
+4%
|
(113)
-1%
|
(111)
+2%
|
(113)
-2%
|
(114)
0%
|
(109)
+4%
|
(110)
0%
|
(112)
-2%
|
(109)
+2%
|
(105)
+4%
|
(102)
+3%
|
|
EPS (Diluted) |
-5.02
N/A
|
-6.66
-33%
|
-10.45
-57%
|
-0.4
+96%
|
-1.83
-358%
|
-0.73
+60%
|
0.11
N/A
|
-2.14
N/A
|
-1.97
+8%
|
-2.64
-34%
|
-3.85
-46%
|
-4.8
-25%
|
-4.32
+10%
|
-4.23
+2%
|
-4.29
-1%
|
-5.12
-19%
|
-5.74
-12%
|
-5.99
-4%
|
-6.2
-4%
|
-5.9
+5%
|
-5.24
+11%
|
-4.99
+5%
|
-5.04
-1%
|
-4.96
+2%
|
-5
-1%
|
-5.01
0%
|
-4.79
+4%
|
-4.81
0%
|
-4.79
+0%
|
-4.64
+3%
|
-3.25
+30%
|
-3.55
-9%
|